Apoptosis inducer 56
Apoptosis inducer 56 is an apoptosis inducer. Apoptosis inducer 56 induces DNA damage (upregulation of γH2AX and p-ATM expression) by minor groove binding. Apoptosis inducer 56 induces intrinsic apoptosis (upregulation of p53 and Bax/Bcl-2 ratio, cleaved caspase-7) via S-phase cell cycle arrest. Apoptosis inducer 56 shows selectivity for cancer cells over normal breast epithelial cells. Apoptosis inducer 56 can be used for the research of breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 952306-31-9
- Fòrmula: C11H17N3O3S
- Peso molecular:271.34
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
|
Caspase-7 |
Bax |
Bcl-2 |
Apoptosis inducer 56 (compound 1) (5-60 μM; 24 h) selectively induces cytotoxicity in MCF-7 human breast cancer cells with an IC50 of 21.18 μM and does not exhibit notable cytotoxicity in non-malignant MCF-10A breast epithelial cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) inhibits proliferation and colony formation, and induces S-phase cell cycle arrest in MCF-7 human breast cancer cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces 45% apoptosis in MCF-7 human breast cancer cells and does not induce apoptosis in non-malignant MCF-10A breast epithelial cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces DNA damage-mediated apoptosis, and induces mitochondrial membrane depolarization in 75.8% of MCF-7 human breast cancer cells[1].
Apoptosis inducer 56 (21.18 μM) activates the DNA damage response (upregulates γ-H2AX, p-ATM, p-Chk2) and suppresses DNA repair (downregulates p-BRCA1) in MCF-7 human breast cancer cells[1].
Apoptosis inducer 56 (21.18 μM; 24 h) induces mitochondria-dependent apoptosis in MCF-7 human breast cancer cells via upregulation of pro-apoptotic proteins, cytochrome c release, caspase activation, and PARP cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 human breast cancer cells, MCF-10A non-malignant breast epithelial cells
-
Concentration:5, 10, 20, 40, 60 μM
-
Incubation Time:24 h
-
Result:Induced cytotoxicity in MCF-7 cells with an IC₅₀ of 21.18 ± 2.01 μM; maintained >70% viability in MCF-10A cells across 5, 10, 20, 40, 60 μM.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Reduced cell proliferation from 83.1% (control) to 66.3%.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Increased S-phase cell accumulation from 17.4% (control) to 30.1%.
-
Cell Line:MCF-7 human breast cancer cells, MCF-10A non-malignant breast epithelial cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Induced 45% apoptosis in MCF-7 cells compared to 2.62% in the control group; maintained 95.8% viability in MCF-10A cells after 24 h treatment.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Caused a substantial increase in TUNEL-positive cells (green fluorescence) compared to the untreated group.
-
Cell Line:MCF-7 human breast cancer cells
-
Concentration:21.18 μM
-
Incubation Time:24 h
-
Result:Upregulated pro-apoptotic Bim and Bax; downregulated anti-apoptotic Bcl2 and Bcl-xL; elevated p53; suppressed survivin; induced cytochrome c release from mitochondria to cytoplasm; upregulated Apaf-1; activated caspase-7 and caspase-9 via cleavage; induced PARP cleavage.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (adult female, 25-28 g)[1]
-
Dosage:1, 2.5, 5, 10 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Detected no significant adverse effects on liver, renal, biochemical, or hematological parameters; observed no treatment-related behavioral deviations; maintained stable body weights across all dose groups; showed no structural abnormalities in liver and kidney tissues via histopathological analysis.
Chemical Information
-
No. CAS 952306-31-9
-
Peso molecular 271.34
-
Fòrmula C11H17N3O3S
-
SMILES
O=C(CCCCCCC(NO)=O)NC1=NC=CS1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Apoptosis inducer 56 Related Classifications
HY-181060 Related Classifications
Powered by Bioz